DE3228502A1 - Verfahren zur herstellung des c1-inaktivators und seine verwendung - Google Patents

Verfahren zur herstellung des c1-inaktivators und seine verwendung

Info

Publication number
DE3228502A1
DE3228502A1 DE19823228502 DE3228502A DE3228502A1 DE 3228502 A1 DE3228502 A1 DE 3228502A1 DE 19823228502 DE19823228502 DE 19823228502 DE 3228502 A DE3228502 A DE 3228502A DE 3228502 A1 DE3228502 A1 DE 3228502A1
Authority
DE
Germany
Prior art keywords
inactivator
solution
hepatitis
stabilizer
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19823228502
Other languages
German (de)
English (en)
Inventor
Helmut Dipl.-Chem. Dr. Heber
Norbert Prof. Dr. Heimburger
Horst 3550 Marburg Naumann
Hermann Dr. Pelzer
Hans-Martin Preis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DE19823228502 priority Critical patent/DE3228502A1/de
Priority to DE8383107374T priority patent/DE3363395D1/de
Priority to EP83107374A priority patent/EP0101935B1/de
Priority to AT83107374T priority patent/ATE19590T1/de
Priority to ES524511A priority patent/ES524511A0/es
Priority to AU17451/83A priority patent/AU564614B2/en
Priority to ZA835561A priority patent/ZA835561B/xx
Priority to CA000433647A priority patent/CA1223201A/en
Priority to JP58137892A priority patent/JPS5944320A/ja
Priority to ES525361A priority patent/ES525361A0/es
Publication of DE3228502A1 publication Critical patent/DE3228502A1/de
Priority to US06/724,050 priority patent/US4915945A/en
Priority to CA000511888A priority patent/CA1236015A/en
Priority to JP4183460A priority patent/JPH07103044B2/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005—Stabilisers against oxidation, heat, light, ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A61L2103/09—Blood or products thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DE19823228502 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung Withdrawn DE3228502A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE8383107374T DE3363395D1 (en) 1982-07-30 1983-07-27 Process for the preparation of the c1 inactivator and its use
EP83107374A EP0101935B1 (de) 1982-07-30 1983-07-27 Verfahren zur Herstellung des C1-Inaktivators und seine Verwendung
AT83107374T ATE19590T1 (de) 1982-07-30 1983-07-27 Verfahren zur herstellung des c1-inaktivators und seine verwendung.
ES524511A ES524511A0 (es) 1982-07-30 1983-07-28 Procedimiento para preparar un inactivador, eventualmente exento de virus de hepatitis y eventualmente liofilizable, de la c1-esterasa del sistema de complemento
CA000433647A CA1223201A (en) 1982-07-30 1983-07-29 Process for the preparation of the c1 inactivator and its use
ZA835561A ZA835561B (en) 1982-07-30 1983-07-29 Process for the preparation of the c1 inactivator and its use
AU17451/83A AU564614B2 (en) 1982-07-30 1983-07-29 Preparation of ci inactivator
JP58137892A JPS5944320A (ja) 1982-07-30 1983-07-29 Ｃ１不活性化剤の調製方法
ES525361A ES525361A0 (es) 1982-07-30 1983-09-05 Procedimiento para preparar un medicamento seguro contra hepatitis que contiene la proteina llamada inactivador cl.
US06/724,050 US4915945A (en) 1982-07-30 1985-04-18 Process for the preparation of the C1 inactivator
CA000511888A CA1236015A (en) 1982-07-30 1986-06-18 Process for the preparation of the c1 inactivator and its use
JP4183460A JPH07103044B2 (ja) 1982-07-30 1992-07-10 Ｃ１不活性化剤を含有する医薬の調製方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung

Publications (1)

Publication Number Publication Date
DE3228502A1 true DE3228502A1 (de) 1984-02-02

Family

ID=6169724

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19823228502 Withdrawn DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE8383107374T Expired DE3363395D1 (en) 1982-07-30 1983-07-27 Process for the preparation of the c1 inactivator and its use

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8383107374T Expired DE3363395D1 (en) 1982-07-30 1983-07-27 Process for the preparation of the c1 inactivator and its use

Country Status (9)

Country Link
US (1) US4915945A (enExample)
EP (1) EP0101935B1 (enExample)
JP (2) JPS5944320A (enExample)
AT (1) ATE19590T1 (enExample)
AU (1) AU564614B2 (enExample)
CA (1) CA1223201A (enExample)
DE (2) DE3228502A1 (enExample)
ES (2) ES524511A0 (enExample)
ZA (1) ZA835561B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222611A3 (en) * 1985-11-08 1988-04-06 Sankyo Company Limited Human complement factors and their therapeutic use

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376367B (de) * 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
FR2618784B1 (fr) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
JP2729484B2 (ja) * 1988-04-28 1998-03-18 株式会社ミドリ十字 アンチトロンビン−▲ｉｉｉ▼の精製方法
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
EP0716611B1 (en) * 1993-09-01 2002-02-06 Stichting Sanquin Bloedvoorziening C1-esterase inhibitor to reduce myocardial injury during acute myocardial infarction
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2013093027A1 (en) 2011-12-22 2013-06-27 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
AU2017316513A1 (en) 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
CA3061279A1 (en) 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
AU2019361252A1 (en) 2018-10-17 2021-06-03 Csl Behring Gmbh Process for purifying C1-INH
CN114096558B (zh) 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322139B2 (enExample) * 1973-11-15 1978-07-06
NL7602846A (nl) * 1976-03-18 1977-09-20 Leuven Res & Dev Vzw Antiplasmine en een antiserum daartegen.
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222611A3 (en) * 1985-11-08 1988-04-06 Sankyo Company Limited Human complement factors and their therapeutic use

Also Published As

Publication number Publication date
JPH07103044B2 (ja) 1995-11-08
JPS5944320A (ja) 1984-03-12
DE3363395D1 (en) 1986-06-12
JPH05306236A (ja) 1993-11-19
ES8501413A1 (es) 1984-11-16
EP0101935B1 (de) 1986-05-07
ZA835561B (en) 1984-03-28
JPH0480886B2 (enExample) 1992-12-21
AU1745183A (en) 1984-02-02
ES525361A0 (es) 1984-11-16
US4915945A (en) 1990-04-10
CA1223201A (en) 1987-06-23
ES8404372A1 (es) 1984-04-16
ATE19590T1 (de) 1986-05-15
AU564614B2 (en) 1987-08-20
ES524511A0 (es) 1984-04-16
EP0101935A1 (de) 1984-03-07

Similar Documents

Publication Publication Date Title
EP0101935B1 (de) Verfahren zur Herstellung des C1-Inaktivators und seine Verwendung
EP0447585B2 (de) Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
DE3877529T2 (de) Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
DE3640513C2 (enExample)
DE69424545T2 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DE68922358T2 (de) Chromatographische Trennung von Plasmaproteinen, insbesondere von Faktor VIII, von Willebrand Faktor, von Fibronectin und von Fibrinogen.
US4340589A (en) Antithrombin preparation and process for the production thereof
DE3876600T2 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
AT407115B (de) Verfahren zur herstellung eines konzentrates von standardisiertem, menschlichem von willebrand-faktor
DE3686470T2 (de) Verfahren zur herstellung des alpha-1-proteinase-inhibitors.
DE69002427T2 (de) Verfahren zur Herstellung eines Konzentrats des Faktor VIII-von Willebrand-Faktor-Komplexes der Blutgerinnung aus Vollplasma.
DE3927111C3 (de) Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate
EP0124506A2 (de) Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
EP0018561A2 (de) Verfahren zur Stabilisierung von Blutgerinnungsfaktoren
DE3043857A1 (de) Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
CH647158A5 (de) Verfahren zur reinigung von interferon.
DE3809991A1 (de) Verfahren zur waermebehandlung von thrombin
JPS59137417A (ja) 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
EP0065256B1 (de) Verfahren zur Herstellung von und danach hergestelltes Plasminogen
EP1326893A2 (de) Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
EP0120835A2 (de) Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachenden Substanzen
DE3001187A1 (de) Verfahren zur herstellung von gereinigtem s-sulfoniertem gamma -globulin
EP0180859B1 (de) Verfahren zur Reinigung sowie Pasteurisierung von Urokinase
DE4431833C1 (de) Verfahren zur Herstellung eines AHF-Konzentrates
DE2404265A1 (de) Verfahren zur gewinnung von immunglobulinen

Legal Events

Date Code Title Description
8130 Withdrawal